BACKGROUND: Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder characterized by circulating plasma cells and a poor prognosis. Although patients who have pPCL benefit from the use of stem cell transplantation (SCT) and novel agents, their prognosis remains inferior to that of patients who have myeloma. METHODS: This was a retrospective analysis of 38 consecutive patients with pPCL who were diagnosed between October 2005 and July 2016 and were registered in the Winship Cancer Institute of Emory University database. Baseline characteristics as well as data about treatment and survival outcomes were collected. RESULTS: The median patient age at diagnosis was 58 years. All patients received a bortezomib-based induction regimen, and 92% received both bortezomib and an immunomodulatory drug (thalidomide or lenalidomide); in addition, 74% of patients underwent autologous SCT (ASCT), and 61% received maintenance therapy. The best response to first-line therapy was a partial response or better in 87% of patients, and 45% had a complete response (CR). The achievement of ≥CR was a predictor for prolonged progression-free survival (PFS) and overall survival (OS). The median PFS was 20 months, and the median OS was 33 months. PFS was prolonged in patients who underwent ASCT compared with those who did not undergo ASCT (25 vs 6 months; P = .004), and patients who received maintenance therapy after ASCT had prolonged median PFS (27 vs 11 months; P = .03) and a trend toward prolonged OS (median, 38 vs 22 months; P = .06) compared with those who did not receive maintenance therapy. CONCLUSIONS: The current data support the use of regimens combining novel agents in the upfront treatment of patients with pPCL as well as the role of ASCT and maintenance therapy for long-term disease control. Cancer 2019;125:416-423.
INTRODUCTION
Plasma cell leukemia (PCL) is a rare but aggressive variant of multiple myeloma (MM). 1 It may occur "de novo" (referred to as primary PCL [pPCL] ) or it may present as an end-stage, leukemic evolution of a refractory MM (thus termed secondary PCL [sPCL] ). pPCL and sPCL constitute approximately 60% and 40% of all PCLs, respectively. On the basis of criteria published by Kyle and colleagues, the diagnosis of PCL requires >2 × 10 3 /μL circulating clonal plasma cells in the peripheral blood, accounting for >20% of the white cell count. 2 However, recent studies have reported that even lower levels of circulating plasma cells are significant and portend a poor prognosis, similar to that observed in patients with PCL. 3, 4 Unlike MM, pPCL usually occurs in younger patients and presents with higher tumor burden. Patients with pPCL exhibit an increased rate of high-risk features associated with poor survival, such as renal failure, advanced disease according to the International Staging System, and complex cytogenetic abnormalities. 1, 5 Before the availability of stem cell transplantation (SCT) and novel agents, the overall survival (OS) of patients who received conventional chemotherapy was <12 months. 6, 7 Later studies suggested a mild improvement in progression-free survival (PFS) and OS among patients with pPCL who underwent autologous SCT (ASCT). 5, 8 Subsequent retrospective studies of patients with pPCL who received upfront treatment with novel agents (especially bortezomib) reported improved PFS and OS compared with historic controls, particularly among those who were able to undergo SCT. [9] [10] [11] Because of the rarity of the disease, to date, only 2 prospective trials have investigated the role of the proteasome inhibitor (PI) bortezomib and the immunomodulatory drug (IMiD) lenalidomide for the upfront treatment of pPCL. Fortunately, those studies confirmed a positive survival trend for patients who received novel agents compared with those who received conventional chemotherapy. In the Italian GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto)
Cancer February 1, 2019 trial, lenalidomide was used in both the induction phase and the maintenance phase, and patients were offered SCT when feasible. The median OS for the entire population was 28 months. In a phase 2 trial presented by the Intergroup Francophone du Myelome (IFM), ASCTeligible patients with pPCL received a bortezomib-based induction regimen followed by tandem SCT; combined bortezomib, lenalidomide, and dexamethasone (VRD) consolidation; and lenalidomide maintenance. This approach resulted in a median OS of 36 months. 12, 13 Despite the impressive improvement in survival outcomes among all patients with MM, especially with the increasing use of SCT and the incorporation of novel agents into the induction and maintenance phases, 14 the survival improvement observed in patients with pPCL still is not on a par with that attained in patients with MM. 15 Here, we present a single-center, retrospective analysis of patients with pPCL with the objective of validating the role of ASCT and the incorporation of PIs and IMiDs into the induction and maintenance phases.
MATERIALS AND METHODS

Data Sources
We conducted a retrospective, Institutional Review Board-approved analysis of patients who were diagnosed with pPCL and registered in the Winship Cancer Institute database at Emory University. According to International Myeloma Working Group criteria, pPCL was defined by the presence of >20% circulating clonal plasma cells and/ or >2 × 10 3 /μL absolute numbers of clonal plasma cells in the peripheral blood. 16 Patients were included in this analysis if they had received at least 1 PI and/or IMiD as part of their induction treatment.
For each patient, we collected baseline data at the time of diagnosis, including age, sex, isotype and quantity of monoclonal protein, chemistry panel, complete blood counts, bone marrow aspirate and core biopsy to evaluate the plasma cell infiltrate, conventional cytogenetics, fluorescence in situ hybridization (FISH) panel, and radiologic evaluation to establish the presence of bone disease. We also collected information about the type and response to first-line treatment, including transplantation and maintenance therapies, as well as the date of first relapse, second-line of treatment, date of second relapse, date of last follow-up, and survival status at the time of last contact. Response to treatment was evaluated according to International Myeloma Working Group response criteria. 16 
Statistical Analysis
The survival outcomes studied included PFS, second PFS, and OS. PFS was defined as the time from diagnosis to first relapse or death from any cause, whichever came first. Second PFS was defined as the time from the start of a second line of therapy to second relapse or death, whichever occurred first. OS was defined as the time from diagnosis to death. PFS, second PFS, and OS curves were plotted using the Kaplan-Meier method, and comparisons were performed using the log-rank test. All hazard ratios (HRs) were estimated with their 95% confidence intervals (CIs) and 2-sided P values. The statistical significance boundary was set at 5%. The Fisher exact test was used for discrete variables. The cutoff date for data analysis was March 2018, and R statistical software (version 3.1.1; R Foundation for Statistical Computing, Vienna, Austria) was used for statistical analyses.
RESULTS
Patients' Characteristics
Thirty-eight consecutive patients who were diagnosed with pPCL between October 2005 and July 2016 and who had received at least 1 PI and/or IMiD as part of their induction treatment were included in the analysis. The median age at diagnosis was 58 years (range, 34-80 years). One-half of patients presented with immunoglobulin G pPCL (53%), whereas 24% and 18% presented with freelight chain and immunoglobulin A pPCL, respectively. At diagnosis, 58% of patients presented with bone disease, and 47% presented with hypercalcemia, whereas 50% had serum creatinine values >2 mg/dL. Patients with pPCL were more likely than those with MM to present with high-risk disease features. Forty-two percent of patients had International Staging System stage 3 disease; and, of 34 patients who had FISH data available, 34% had high-risk disease, as defined by the presence of at least 1 high-risk cytogenetic abnormality, including translocation t(4;14) or t(14;16) and deletion del(17p).
First-Line Treatment and Response to Treatment
Data on induction regimens are listed in Table 1 . All patients received a bortezomib-based induction regimen, and 35 of 38 (92%) received a combination of bortezomib and an IMiD (thalidomide or lenalidomide). The median number of induction cycles was 3 (range, 1-15 cycles), and the median number of induction cycles for patients who received novel agents with or without conventional chemotherapy was 2 and 4 cycles, respectively.
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The overall response rate (ORR) after the induction phase was 82%: 45% of patients achieved at least a very good partial response (VGPR), and 18% achieved a complete response (CR) ( Table 2) .
Twenty-eight patients underwent ASCT after induction treatment, and the median time to ASCT was 3 months (range, 2-12 months). Ten patients did not proceed to ASCT: 4 patients because of suboptimal response or progression after induction, 4 according to their preference, and 2 because of age (>75 years).
Maintenance therapy was received by 23 patients (22 after ASCT); 5 patients did not receive maintenance after ASCT because of patient preference (n = 4) or disease progression (n = 1). The standard maintenance approach for this high-risk population consisted of a combination of a PI, an IMiD, and dexamethasone administered up to 3 years. Thereafter, treatment was switched to single-agent maintenance. 17 Most patients received VRD maintenance (n = 14); whereas, in 3 patients, combined carfilzomib, pomalidomide, and dexamethasone was chosen because of a suboptimal response after induction with VRD. Two patients received either ixazomib or carfilzomib instead of bortezomib, and 1 patient received pomalidomide rather than lenalidomide, at the treating physician's discretion.
The best response to first-line treatment was at least a partial response (PR) in 87% of patients, and 68% and 45% of these patients achieved at least a VGPR or a CR, respectively. The median time to best response was 5 months (range, 1-24 months). The achievement of at least a CR was associated with significantly prolonged median PFS (25 vs 11 months; HR, 0.4; P = .02) and OS (63 vs 28 months; HR, 0.4; P = .04) compared with those who achieved a PR or a VGPR.
Second-Line Treatment
Thirty-one patients progressed after first-line therapy, and 4 (13%) of these patients relapsed with central nervous system involvement by plasma cells. Twenty-four patients received a second line of treatment. Ten of these patients received a triplet combination based on 2 novel agents and dexamethasone (VRD; carfilzomib, lenalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone; elotuzumab, lenalidomide, and dexamethasone; or daratumumab, pomalidomide, and dexamethasone), 10 patients received a combination of at least 1 novel agent plus conventional chemotherapy, and 4 patients underwent ASCT in second remission. The median number of treatment lines was 2 (range, 1-8 treatment lines).
Survival Outcomes
After a median follow-up of 88 months (95% CI, 59 months to not available), 25 patients have died. Only 1 patient died within the first month from diagnosis, for an early mortality rate of 3%. Cancer February 1, 2019 In the overall population, the median PFS was 20 months (95% CI, 11-33 months), and 28% of patients were alive and progression free at 3 years (Fig. 1A) . The median second PFS was 6 months (95% CI, 4-28 months). The median overall survival was 33 months (95% CI, 25-53 months), and 39% of patients remained alive at 3 years (Fig. 1B) .
The median PFS was significantly longer in patients who received ASCT upfront as compared with those who did not (25 vs 6 months; HR, 0.3; P = .004) (Fig. 2A) . Furthermore, a trend toward improved OS, although it was not statistically significant, was observed among patients who underwent ASCT upfront compared with those who did not (median, 36 vs 26 months; HR, 0.5; P = .08) (Fig. 2B) .
The receipt of maintenance therapy after ASCT significantly prolonged median PFS (27 vs 11 months; HR, 0.3, P = .03), with a trend toward a longer median OS (38 vs 22; HR, 0.4, P = .06) compared with no maintenance (Fig. 3) .
In patients (n = 17) who received an intensive treatment strategy, consisting of a PI plus IMiD induction regimen, consolidation with a single ASCT, and followed by a 3-drug maintenance regimen, the median PFS was 33 months (95% CI, 25 months to not available), and the median OS was 63 months (95% CI, 33 months to not available), with 3-year PFS and OS rates of 47% and 58%, respectively.
In these patients, no differences in terms of the ORR (90% vs 75%; P = .7), the CR rate (20% vs 17%; P = 1), median PFS (25 vs 36 months; P = .3), or median and OS (38 vs 43 months; P = 1) were observed in those who received novel agents with or without intensive chemotherapy, respectively, as part of induction therapy.
DISCUSSION
Before the introduction of ASCT and novel agents, conventional chemotherapy proved to be inadequate for disease control in patients with pPCL, offering a median OS <12 months. 6, 18 Given the rarity of the disease, the first reports on the use of novel agents in this setting were retrospective studies. Bortezomib demonstrated the ability to induce an objective response in up to 78% of patients, thus resulting into a prolonged median OS (range, 18-28 months) compared with conventional chemotherapy. 9, 10, 19, 20 Similarly, lenalidomide (although in small retrospective reports) demonstrated some degree of activity in patients with pPCL. 21, 22 The only 2 prospective trials published to date evaluating patients with newly diagnosed pPCL were conducted by the GIMEMA and IFM groups. The GIMEMA group evaluated 23 patients with untreated pPCL who received lenalidomide-dexamethasone induction, with the option to proceed to SCT if eligible, and subsequently received lenalidomide maintenance. 23 For the entire population, the median PFS was 15 months, and the median OS was 28 months. However, the survival advantage was exclusively confined to patients who underwent transplantation, and no improvement was observed among those who did not undergo SCT in terms of median PFS (27 vs 2 months) and OS (not reached vs 12 months).
The IFM group conducted a phase 2 trial in 40 patients with untreated pPCL who were eligible for SCT. After bortezomib-based induction, patients could proceed to either a double ASCT followed by 1 year of RVD maintenance or a tandem ASCT/allogeneic SCT. For the entire population the median PFS was 15 months, and the median OS was 36 months. 12 Here, we present the results of a single-center, retrospective analysis of patients with pPCL who received treatment at the Winship Cancer Institute of Emory University. To our knowledge, this is the first extensive report on the combined use of PIs and IMiDs as initial treatment for patients with pPCL: 92% and 53% of patients analyzed received induction and maintenance regimens, respectively, in which a PI (bortezomib, carfilzomib, or ixazomib) was combined with an IMiD (thalidomide, lenalidomide, or pomalidomide).
The ORR and the rate of attaining at least a VGPR (87% and 68%, respectively) in our study compare favorably with those reported in prospective studies using either lenalidomide (74% and 39%, respectively) or bortezomib (69% and 59%, respectively).
12,23 Katodritou et al. reported a significant survival advantage in patients who achieved at least a VGPR as their best response during first-line therapy. In our current study, patients who achieved at least a CR as their best response had significantly longer PFS (median, 25 vs 11 months) and OS (median, 63 vs 28 months) compared with those who achieved a PR or a VGPR only, thus highlighting the benefit of profound cytoreduction in obtaining longterm disease control. 10 The efficacy displayed by the incorporation of PIs and IMiDs in the induction phase of pPCL treatment is also reflected by the lower early mortality rate (within the first month) observed among our patients (3%) compared with the early mortality rates reported in the National Cancer Institute's Surveillance, Epidemiology, and End Results program analysis (15% among patients who received treatment after 2006) and in the retrospective analysis conducted by Katodritou and colleagues (6%). 15 It is noteworthy that the addition of intensive chemotherapy to novel agents as induction therapy did not translate into significant differences in terms of ORR, median PFS, or OS compared with intensive chemotherapy-sparing regimens. However, given the retrospective nature of this study and the lack of randomization, these results need to be cautiously interpreted and should be validated in a prospective trial.
In the current study, both the median PFS (20 months) and the median OS (33 months) for the entire population compared favorably with those reported using lenalidomide-based (15 and 28 months, respectively) and bortezomib-based (12 and 18 months, respectively) regimens. 13, 23 Although cross-trial comparisons are difficult to perform, in our study, combining bortezomib and IMiDs appeared to improve the ORR (82% vs 69%) and the CR rate (44% vs 33%) obtained after the induction phase, reducing the rate of patients who had primary refractory disease (5% vs 26%,) compared with the bortezomib-based induction regimen adopted in the IFM trial. This, along with a longer duration of maintenance (3 years vs 1 year), might account for the better PFS observed in our trial.
We confirmed that the greatest survival benefit, in terms of both PFS (25 vs 6 months) and OS (36 vs 26 months), was observed among the patients who underwent ASCT, thus validating the role of ASCT as a standard consolidation approach after initial cytoreduction, as previously described. 13, 23 In this light, the promising 6-month OS (92%) observed in the overall population supports the benefit of combining bortezomib with IMiDs upfront to obtain rapid disease control and enable transplantation-eligible patients to proceed to ASCT.
Allogeneic SCT has been regarded as a potentially curative approach for PCL. However, in large, retrospective analyses comparing autologous versus allogeneic SCT, patients in the allogeneic SCT group, although they had better disease control, also had significantly higher treatment-related mortality, ultimately resulting in the lack of a survival benefit. 8, 24 Indeed, the adoption of reduced-intensity conditioning regimens and the availability of new drugs as post-transplantation consolidation/maintenance might redefine the role of allogeneic SCT. The currently ongoing Bone and Marrow Transplant Clinical Trials Network BMT CTN 1302 study (Clinicaltrials.gov identifier NCT02440464) will provide further insight into the role of allogeneic SCT and the use of ixazomib maintenance for patients with pPCL.
Although maintenance treatment has been proven to prolong both PFS and OS in patients with MM, thus becoming a standard of care, little evidence is available about the role of continuous treatment in pPCL. 25 In our cohort, 23 patients received maintenance therapy after ASCT in first remission and, notably, 19 of 22 received a 3-drug regimen consisting of 2 novel agents plus dexamethasone. Patients who received maintenance treatment after ASCT had significantly prolonged PFS (27 vs 11 months) and OS (38 vs 22 months) compared with those who did not receive maintenance. Because this advantage was reported previously in patients with high-risk MM, 17 the evidence endorses the use of a 3-drug maintenance strategy combining PIs and IMiDs to obtain long-term disease control in patients with pPCL.
In our analysis, despite access to novel, secondgeneration agents, the median second PFS was only 6 months, a result similar to that reported by Katodritou et al. (median, 6.5 months), 13 without significant differences among patients who did and did not receive maintenance (median, 3 vs 7 months, respectively; P = .4). Moreover, 13% of patients who relapsed presented with central nervous system involvement. The aggressiveness of the disease at first relapse and its refractoriness to second-line therapies, as established by the short second PFS and the pattern of relapse, suggest that the OS of patients with pPCL depends greatly on the first-line treatment, thus supporting the role of an intensive treatment strategy upfront.
A small cohort of patients in our data set (18%) achieved long-term survival, remaining alive at 5 years. In this subgroup, only 1 patient had high-risk features according to FISH analysis, whereas 3 patients were positive for t (11;14) . All but 1 patient underwent ASCT and received VRD maintenance; 5 of these 7 patients were in at least VGPR after induction and subsequently obtained a CR. Despite the limited number of patients, these data suggest that the absence of high-risk cytogenetics and an early and deep response to induction treatment may characterize a subset of patients in whom long-term survival can be achieved, particularly with the use of intensive and prolonged treatment.
In conclusion, we present results from the first large cohort of patients with pPCL who received treatment with a combination of PIs and IMiDs during the induction and maintenance phases. We validated the role of ASCT as a consolidation strategy to obtain durable remissions and prolonged survival and demonstrated that maintenance treatment is associated with better survival. However, despite the encouraging results, the prognosis for patients with pPCL remains largely unsatisfactory compared with that for patients with MM. Moving forward, newer compounds, such as second-generation and third-generation PIs and IMiDs, monoclonal antibodies, and intensive treatment strategies, may continue to improve the survival of patients with pPCL.
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